Characteristics
|
OS
| | |
DFS
|
---|
Before PSM
|
After PSM
|
Before PSM
|
After PSM
|
---|
HR (95CI)
|
P-value
|
HR (95CI)
|
P-value
|
HR (95CI)
|
P-value
|
HR (95CI)
|
P-value
|
---|
γ-GT ≤ 54 U/L
|
Tumor number (Multiple vs Single)
|
2.11 (1.55–2.87)
|
< 0.001
|
1.97 (1.33–2.93)
|
0.001
|
2.07 (1.61–2.65)
|
< 0.001
|
2.18 (1.59–2.98)
|
< 0.001
|
Tumor diameter (cm)
|
1.11 (1.07–1.15)
|
< 0.001
|
1.11 (1.05–1.17)
|
< 0.001
|
1.08 (1.04–1.12)
|
< 0.001
|
1.08 (1.03–1.13)
|
0.003
|
Capsule (Absent vs Present)
|
1.36 (1.02–1.81)
|
0.039
|
1.41 (0.95–2.09)
|
0.085
|
–
|
–
|
–
|
–
|
MVI (Absent vs Present)
|
1.58 (1.22–2.06)
|
0.001
|
1.57 (1.10–2.26)
|
0.014
|
1.44 (1.16–1.79)
|
0.001
|
1.45 (1.08–1.95)
|
0.014
|
PA-TACE (Yes vs No)
|
0.85 (0.65–1.11)
|
0.222
|
0.89 (0.64–1.23)
|
0.471
|
0.86 (0.69–1.08)
|
0.190
|
0.91 (0.71–1.18)
|
0.483
|
γ-GT > 54 U/L
|
TBil (μmol/L)
|
1.01 (1.00–1.03)
|
0.036
|
1.02 (1.01–1.04)
|
0.009
|
1.01 (1.00–1.03)
|
0.028
|
1.03 (1.01–1.05)
|
< 0.001
|
AFP (> 400 vs 400 ng/mL)
|
1.71 (1.39–2.10)
|
< 0.001
|
1.71 (1.32–2.22)
|
< 0.001
|
1.43 (1.20–1.71)
|
< 0.001
|
1.47 (1.18–1.84)
|
0.001
|
Tumor number (Multiple vs Single)
|
–
|
–
|
–
|
–
|
1.25 (1.01–1.56)
|
0.042
|
1.08 (0.82–1.42)
|
0.589
|
Tumor diameter (cm)
|
1.06 (1.04–1.09)
|
< 0.001
|
1.07 (1.04–1.10)
|
< 0.001
|
1.03 (1.01–1.05)
|
0.008
|
1.04 (1.01–1.06)
|
0.005
|
Capsule (Absent vs Present)
|
1.33 (1.05–1.68)
|
0.019
|
1.43 (1.05–1.95)
|
0.024
|
–
|
–
|
–
|
–
|
MVI (Absent vs Present)
|
1.43 (1.14–1.79)
|
0.002
|
1.21 (0.89–1.64)
|
0.219
|
1.37 (1.13–1.65)
|
0.001
|
1.19 (0.92–1.54)
|
0.174
|
PA-TACE (Yes vs No)
|
0.69 (0.55–0.86)
|
0.001
|
0.66 (0.52–0.85)
|
0.001
|
0.76 (0.63–0.91)
|
0.003
|
0.74 (0.60–0.92)
|
0.006
|
- Note: OS overall survival; DFS disease-free survival; HR hazard ratio; CI confidence interval; PSM propensity score matching; γ-GT gamma-glutamyl transferase; TBil total bilirubin; AFP alpha-fetoprotein; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization